Prologue Medicines
Renee Deming currently serves as the Head of Strategy and Operations at Prologue Medicines since July 2024 and is a member of the old girls club from April 2024. Prior experience includes significant roles at Enveda Biosciences, where Renee held the positions of VP and Director of Program Strategy and Business Development from November 2022 to July 2024, and at Cyclerion, serving as Senior Manager and Manager of External Innovation and Corporate Development, along with a role as Senior Scientist between October 2019 and October 2022. Further experience includes a tenure at Ironwood Pharmaceuticals as a Scientist and Senior Associate Scientist from August 2010 to 2019, and an Associate Researcher position at Takeda from January 2009 to August 2010. Educational qualifications include a BS in Cell and Molecular Biology and Genetics from Boston University, as well as an MS in Biotechnology Management from Harvard Extension School, complemented by further studies at Harvard University.
This person is not in any teams
This person is not in any offices
Prologue Medicines
1 followers
Prologue is designing powerful new medicines by unlocking the viral proteome. The company’s state-of-the-art DELVE™ Platform systematically identifies and evaluates viral proteins and their unique features for their potential to precisely regulate human physiology. By co-opting viral evolution, Prologue is expanding the functional boundaries of proteins encoded by the human genome to create new programmable medicines. Prologue was founded by Flagship Pioneering in 2021.